Inhibition of cytochrome P450 3A by acetoxylated analogues of resveratrol in in vitro and in silico models

被引:14
|
作者
Basheer, Loai [1 ]
Schultz, Keren [1 ]
Kerem, Zohar [1 ]
机构
[1] Hebrew Univ Jerusalem, Robert H Smith Fac Agr Food & Environm, Inst Biochem Food Sci & Nutr, POB 12, IL-76100 Rehovot, Israel
来源
SCIENTIFIC REPORTS | 2016年 / 6卷
关键词
HERB-DRUG INTERACTION; P450-MEDIATED METABOLISM; STRUCTURAL BASIS; CYP3A4; RAT; MECHANISM; TRANSPORT; ENZYMES; LIVER; BIOAVAILABILITY;
D O I
10.1038/srep31557
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Many dietary compounds, including resveratrol, are potent inhibitors of CYP3A4. Here we examined the potential to predict inhibition capacity of dietary polyphenolics using an in silico and in vitro approaches and synthetic model compounds. Mono, di, and tri-acetoxy resveratrol were synthesized, a cell line of human intestine origin and microsomes from rat liver served to determine their in vitro inhibition of CYP3A4, and compared to that of resveratrol. Docking simulation served to predict the affinity of the synthetic model compounds to the enzyme. Modelling of the enzyme's binding site revealed three types of interaction: hydrophobic, electrostatic and H-bonding. The simulation revealed that each of the examined acetylations of resveratrol led to the loss of important interactions of all types. Triacetoxy resveratrol was the weakest inhibitor in vitro despite being the more lipophilic and having the highest affinity for the binding site. The simulation demonstrated exclusion of all interactions between tri-acetoxy resveratrol and the heme due to distal binding, highlighting the complexity of the CYP3A4 binding site, which may allow simultaneous accommodation of two molecules. Finally, the use of computational modelling may serve as a quick predictive tool to identify potential harmful interactions between dietary compounds and prescribed drugs.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Cytochrome P450 3A, NADPH cytochrome P450 reductase and cytochrome b5 in the upper airways in horse
    Tyden, E.
    Olsen, L.
    Tallkvist, J.
    Tjalve, H.
    Larsson, P.
    RESEARCH IN VETERINARY SCIENCE, 2008, 85 (01) : 80 - 85
  • [22] Pharmacokinetic and Pharmacodynamic Consequences of Cytochrome P450 3A Inhibition on Mitragynine Metabolism in RatsS
    Kamble, Shyam H.
    Obeng, Samuel
    Leon, Francisco
    Restrepo, Luis F.
    King, Tamara I.
    Berthold, Erin C.
    Kanumuri, Siva Rama Raju
    Gamez-Jimenez, Lea R.
    Pallares, Victoria L. C.
    Patel, Avi
    Ho, Nicholas P.
    Hampson, Aidan
    McCurdy, Christopher R.
    McMahon, Lance R.
    Wilkerson, Jenny L.
    Sharma, Abhisheak
    Hiranita, Takato
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385 (03): : 180 - 192
  • [23] In vitro and in vivo Inhibitory Effects of Glycyrrhetinic Acid on Cytochrome P450 3A Activity
    Li, Hai Yun
    Xu, Wen
    Su, Juan
    Zhang, Xi
    Hu, Li Wei
    Zhang, Wei Dong
    PHARMACOLOGY, 2010, 86 (5-6) : 287 - 292
  • [24] Inhibitory Effect of Lygodium Root on the Cytochrome P450 3A Enzyme in vitro and in vivo
    Zhou, Yunfang
    Hua, Ailian
    Zhou, Quan
    Geng, Peiwu
    Chen, Feifei
    Yan, Lianhe
    Wang, Shuanghu
    Wen, Congcong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 1909 - 1919
  • [25] QSAR modeling of in vitro inhibition of cytochrome P450 3A4*
    Mao, Boryeu
    Gozalbes, Rafael
    Barbosa, Frederique
    Migeon, Jacques
    Merrick, Sandra
    Kamm, Kelly
    Wong, Eric
    Costales, Chester
    Shi, Wei
    Wu, Cheryl
    Froloff, Nicolas
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2006, 46 (05) : 2125 - 2134
  • [26] Interaction of cytochrome P450 3A inhibitors with P-glycoprotein
    Yasuda, K
    Lan, LB
    Sanglard, D
    Furuya, K
    Schuetz, JD
    Schuetz, EG
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (01): : 323 - 332
  • [27] Cloning, expression, and characterization of cytochrome P450 3A in minipig
    Soucek, P
    Anzenbacher, P
    Zuber, R
    Anzenbacherová, E
    Guengerich, FP
    TOXICOLOGY, 2001, 164 (1-3) : 146 - 146
  • [28] Metabolism of Beclomethasone Dipropionate by Cytochrome P450 3A Enzymes
    Roberts, Jessica K.
    Moore, Chad D.
    Ward, Robert M.
    Yost, Garold S.
    Reilly, Christopher A.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 345 (02): : 308 - 316
  • [29] Cytochrome P450 3A polymorphisms and immunosuppressive drugs:: an update
    Anglicheau, Dany
    Legendre, Christophe
    Beaune, Philippe
    Thervet, Eric
    PHARMACOGENOMICS, 2007, 8 (07) : 835 - 849
  • [30] Cytochrome P450 3A pharmacogenetics: the road that needs traveled
    Flockhart, DA
    Rae, JM
    PHARMACOGENOMICS JOURNAL, 2003, 3 (01): : 3 - 5